Inventor · disambiguated record
Erik James Hicken
Also filed as: HICKEN ERIK JAMES
19 granted patents·2 pending applications·87 citations·filing 2009–2023
92Inventor score
Top patents by PatentIndex Score
21 records- 0196US10125134B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2017·Granted Nov 13, 2018·43 cites·9 claims
- 0294US11414404B2Compounds for the treatment of BRAF-associated diseases and disordersARRAY BIOPHARMA INC·Filed 2020·Granted Aug 16, 2022·5 cites·14 claims
- 0393US10633381B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2018·Granted Apr 28, 2020·8 cites·7 claims
- 0491US11267812B2KRAS G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2017·Granted Mar 8, 2022·11 cites·34 claims
- 0589US10730880B24,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Aug 4, 2020·4 cites·25 claims
- 0681US11932633B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted Mar 19, 2024·2 cites·41 claims
- 0781US9670208B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Jun 6, 2017·4 cites·19 claims
- 0878US10189845B24,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitorsARRAY BIOPHARMA INC·Filed 2015·Granted Jan 29, 2019·2 cites·20 claims
- 0975US9174981B2Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitorsBOYS MARK LAURENCE·Filed 2011·Granted Nov 3, 2015·3 cites·30 claims
- 1074US8557809B2Triazolopyridine compounds as PIM kinase inhibitorsALLEN SHELLEY·Filed 2009·Granted Oct 15, 2013·2 cites·17 claims
- 1172US9809590B2Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2015·Granted Nov 7, 2017·1 cites·29 claims
- 1271US11634409B2Compounds for the treatment of BRAF-associated diseases and disordersARRAY BIOPHARMA INC·Filed 2022·Granted Apr 25, 2023·0 cites·42 claims
- 1371US8575145B2Triazolopyridine compounds as PIM kinase inhibitorsALLEN SHELLEY·Filed 2009·Granted Nov 5, 2013·2 cites·29 claims
- 1470US2024124474A1Her2 mutation inhibitorsARRAY BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1567US11834453B2Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitorsARRAY BIOPHARMA INC·Filed 2021·Granted Dec 5, 2023·0 cites·28 claims
- 1667US10669269B2Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Jun 2, 2020·0 cites·16 claims
- 1764US11028093B24,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitorsARRAY BIOPHARMA INC·Filed 2020·Granted Jun 8, 2021·0 cites·19 claims
- 1854US12447153B2HER2 mutation inhibitorsARRAY BIOPHARMA INC·Filed 2022·Granted Oct 21, 2025·0 cites·18 claims
- 1950US8895550B2Triazolopyridine compounds as PIM kinase inhibitorsARRAY BIOPHARMA INC·Filed 2013·Granted Nov 25, 2014·0 cites·22 claims
- 2044US8987251B2Triazolopyridine compounds as PIM kinase inhibitorsARRAY BIOPHARMA INC·Filed 2013·Granted Mar 24, 2015·0 cites·33 claims
- 2141US2014228349A15,7-substituted-imidazo[1,2-c]pyrimidinesARRAY BIOPHARMA INC·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Erik James Hicken files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →